We have partnered with INRA, since the company’s inception to provide a complete standardized procedure from stool collection to patient administration for preparing frozen, live and ready-to-use inocula that meet the standard requirements of good practice to applied use in the pharmaceutical industry.

MaaT Pharma and Biocodex joined forces to industrialize the Fecal Microbiota Transfer.
This agreement has two main components, one is to establish the long term blueprint of our industrial platform and the other one, to develop an oral form of our product.

MaaT Pharma is a partner of the collaborative LUMIERE project aiming at developing therapies to overcome primary resistance of anti-cancer treatments using the power of the Microbiome.
This project is coordinated by the Institute “Gustave Roussy” and includes key academics leading the Microbiome research such as INRA, INSERM, Méditerranée Infection Foundation, Institut Pasteur, Unicancer, Université Paris-Sud, Universite Paris-Descartes as well as leading Pharma corporations such as AstraZeneca, and Sanofi.

The implementation of our GMP platform dedicated to FMT, the 1^st in Europe, was realized in 2016 in collaboration with Accinov. The new formulation MaaT013 is also produced under this agreement and will allow MaaT Pharma to supply the whole of Europe with our microbiota-based experimental drugs.

MaaT Pharma has started a collaboration with EMI-Wissler to develop and industrialize the collection device which guaranties the standardization and safety of the starting material collection.

MaaT Pharma and UCA have been working together on the development of a new model for dysbiosis in vitro assessment.